Business
Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC
Lyon (France), March 26, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its participation in the upcoming 26th World Vaccine Congress, which will take place from March 31 to April 2, 2026 at the Walter E. convention center in Washington, D.C. Led by the Company´s Chief Executive Officer, Thomas Lingelbach, a team of Valneva´s senior executives will participate in multiple events throughout the conference. On April 1, 2026, at 9:40 am EST, Susa
About this update from Valneva Se
[{"type":"image","alt":"VALNEVA","displaySize":"","headline":null,"caption":"VALNEVA","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":44,"url":"https://media.zenfs.com/en/globenewswire.com/29df7eb71c048b91fe66a95a1cd8b1d6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BUq09jfPjcCOrfwrLIxO7A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYy/https://media.zenfs.com/en/globenewswire.com/29df7eb71c048b91fe66a95a1cd8b1d6","width":300,"height":44}},"lazy":false},{"type":"text","content":"Lyon (France), March 26, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its participation in the upcoming 26th World Vaccine Congress, which will take place from March 31 to April 2, 2026 at the Walter E. convention center in Washington, D.C. Led by the Company´s Chief Executive Officer, Thomas Lingelbach, a team of Valneva´s senior executives will participate in multiple events throughout the conference.","length":461,"tagName":"p"},{"type":"text","content":"On April 1, 2026, at 9:40 am EST, Susanne Eder-Lingelbach, Vice President Clinical Development at Valneva, will present “Vaccine Development updates for chikungunya – Phase IV and real-world evidence studies".","length":214,"tagName":"p"},{"type":"text","content":"Valneva and its partner Instituto Butantan recently announced the launch of a pilot vaccination campaign with Valneva’s single shot chikungunya vaccine IXCHIQ® in Brazil, which will serve as the basis for post-marketing commitment studies. Over 12,000 people have already been vaccinated as part of this campaign which evaluates the effectiveness and safety of IXCHIQ® in a real-world setting.","length":393,"tagName":"p"},{"type":"text","content":"On the same day at 9:55 am EST, Valneva’s Chief Medical Officer, Dr. Juan Carlos Jaramillo, will take part in the “chikungunya and mosquito-borne vaccines: bridging outbreak response, manufacturing and market creation” panel discussion alongside Dr Mandeep Singh Dhingra, Head of R&D Programs at the Coalition for Epidemic Preparedness Innovations, Mary Magubo, Head of Advocacy Communication at the Ministry of Health Kenya, and moderated by Sushant Sahastrabuddhe, Deputy Director General, International Vaccine Institute.","length":528,"tagName":"p"},{"type":"text","content":"The Company will also use the event as an opportunity to m...